缺血性心肌病心力衰竭患者应用参麦注射液联合左卡尼汀治疗的效果分析
|
摘要
目的观察缺血性心肌病心力衰竭患者应用参麦注射液联合左卡尼汀治疗的效果。方法选取2015年1月～2017年12月于我院就诊的缺血性心肌病心力衰竭患者70例,按照随机数字表法分为研究组和对照组,每组各35例。对照组给予常规治疗,实验组在此基础上给予参麦注射液联合左卡尼汀治疗,疗程半个月。观察两组患者治疗前和治疗6个月后心功能指标、血清NT-proNP和CRP水平、临床疗效以及不良反应发生情况。结果与治疗前相比,两组患者LVEF、SV、CO均明显升高,LVDD、LVSD均显著降低,且实验组的LVEF、SV、CO明显高于对照组,LVDD、LVSD显著低于对照组,差异有统计学意义(P <0.05);治疗后两组患者的CRP、NT-proBNP较治疗前均显著降低,且实验组的CRP、NT-proBNP显著低于对照组,差异有统计学意义(P <0.05);实验组患者治疗有效率显著高于对照组(91.43%和71.42%,P <0.05);两组患者不良反应发生率差异无统计学意义(14.29%和8.57%,P> 0.05)。结论参麦注射液联合左卡尼汀治疗缺血性心肌病心力衰竭能明显改善患者心功能,提高临床疗效,值得推广。
Objective To observe effect of Shenmai injection combined with levularnitine in the treatment of ischemic cardiomyopathy patients with heart failure. Methods 70 patients with congestive cardiomyopathy heart failure received in our hospital during January 2015 to December 2017 were randomly allocated to an study group and a control group,with 35 patients in each.The control group received regular treatment,while the study group further received Shenmai injection combined with levularnitine treatment for half a month.Before and 6 months after treatment,cardiac function indexes,serum nt-pronp and CRP levels,clinical efficacy and adverse reactions occurred in the two groups were observed. Results Compared with treatment before,LVEF,SV and CO were significantly increased in both groups,while LVDD and LVSD were significantly decreased.LVEF,SV and CO in the study group were significantly higher than those in the control group,while LVDD and LVSD were significantly lower than those in the control group,with statistically significant difference(P < 0.05).After the treatment of two groups of patients with CRP,nt-probnp was significantly lower than treatment before,and the study group of CRP and ntprobnp were significantly lower than the control group(91.43% and 71.42%,P < 0.05).The treatment efficiency of the experimental group was significantly higher than that of the control group(P < 0.05).There was no significant difference in the incidence of adverse reactions between the two groups(14.29%,8.57%,P < 0.05). Conclusion Shenmai injection combined with l-carnitine in the treatment of heart failure in patients with ischemic cardiomyopathy can significantly improve the cardiac function,enhance the clinical efficacy,which is worthy of promotion.
Objective To observe effect of Shenmai injection combined with levularnitine in the treatment of ischemic cardiomyopathy patients with heart failure. Methods 70 patients with congestive cardiomyopathy heart failure received in our hospital during January 2015 to December 2017 were randomly allocated to an study group and a control group,with 35 patients in each.The control group received regular treatment,while the study group further received Shenmai injection combined with levularnitine treatment for half a month.Before and 6 months after treatment,cardiac function indexes,serum nt-pronp and CRP levels,clinical efficacy and adverse reactions occurred in the two groups were observed. Results Compared with treatment before,LVEF,SV and CO were significantly increased in both groups,while LVDD and LVSD were significantly decreased.LVEF,SV and CO in the study group were significantly higher than those in the control group,while LVDD and LVSD were significantly lower than those in the control group,with statistically significant difference(P < 0.05).After the treatment of two groups of patients with CRP,nt-probnp was significantly lower than treatment before,and the study group of CRP and ntprobnp were significantly lower than the control group(91.43% and 71.42%,P < 0.05).The treatment efficiency of the experimental group was significantly higher than that of the control group(P < 0.05).There was no significant difference in the incidence of adverse reactions between the two groups(14.29%,8.57%,P < 0.05). Conclusion Shenmai injection combined with l-carnitine in the treatment of heart failure in patients with ischemic cardiomyopathy can significantly improve the cardiac function,enhance the clinical efficacy,which is worthy of promotion.
引文
[1]白巧艳,李巍,倪春梅.左西孟旦联合左卡尼汀治疗顽固性心力衰竭患者的效果观察[J].中国当代医药,2018,25(1):125-128.
[2]余世成,冯俊,孙召金,等.参麦注射液对缺血性心肌病左室射血和心肺运动功能的影响[J].安徽医药,2017,21(4):731-734.
[3]张国强,李征,朱志远.左卡尼汀联合参麦注射液治疗缺血性心肌病心力衰竭疗效分析[J].新中医,2014,46(12):33-34.
[4]中华医学会心血管病学分会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):3-10.
[5]乔玉冰,向东.左卡尼汀联合美托洛尔治疗缺血性心肌病心力衰竭的临床疗效观察[J].华南国防医学杂志,2015,6(3):234-236.
[6]吕凤仙.曲美他嗪与左卡尼汀联合用药治疗老年缺血性心肌病心力衰竭患者的疗效分析[J].中国社区医师,2017,33(12):55-56.
[7]胡小洋.参麦注射液与左卡尼汀联用对老年患者缺血性心肌病心力衰竭的临床疗效评价[J].抗感染药学,2016,13(5):1166-1168.
[8]郭文安.缺血性心肌病心力衰竭应用左卡尼汀及参麦注射液治疗的疗效评价[J].中国实用医药,2014,9(7):190.
[9]郭春香.左卡尼汀联合参麦注射液治疗充血性心力衰竭的临床研究[J].中国现代药物应用,2015,9(19):137-138.
[10]赵大鹏.缺血性心肌病心力衰竭应用左卡尼汀与参麦联合治疗的临床分析[J].中国现代药物应用,2016,10(4):154-155.
[11]占凡.参麦注射液联合左卡尼汀治疗老年缺血性心肌病心力衰竭的临床疗效[J].中国老年学,2013,33(16):3990-3991.
[12]田韵,何河.左卡尼汀联合参麦注射液治疗老年缺血性心肌病心力衰竭疗效观察[J].现代中西医结合杂志,2014,23(34):3820-3822.
[13]董赛晓,邓志鹏,白丽秀,等.左卡尼汀注射液联合参麦注射液治疗缺血性心肌病心力衰竭疗效观察[J].中国中医急症,2012,21(5):817-818.
[14]李芳学.左卡尼汀联合参麦注射液治疗缺血性心肌病心力衰竭35例效果观察[J].山东医药,2010,50(51):59-60.
[15]陈俊媛.左卡尼汀联合参麦注射液治疗缺血性心肌病心力衰竭的临床研究[J].中国卫生标准管理,2015,6(13):171-172.
[16]邹宁.参麦注射液联合左卡尼汀治疗慢性心力衰竭临床研究[J].亚太传统医药,2017,13(22):156-157.
[17]吴保军.参麦注射液联合左卡尼汀对缺血性心肌病心力衰竭病人神经内分泌因子、左室重构及心功能的影响[J].中西医结合心脑血管病杂志,2017,15(15):1864-1866.
[18]陆建洪,张树鑫,陈捷.参麦注射液联合左卡尼汀治疗缺血性心肌病心力衰竭疗效观察[J].中华中医药学刊,2016,34(2):470-472.
[19]周婵娟.左卡尼汀联合曲美他嗪治疗老年缺血性心肌病心力衰竭临床分析[J].心血管病防治知识(学术版),2016,7(11):74-75.
[20]周先立.参麦注射液联合左卡尼汀治疗缺血性心肌病心力衰竭的疗效[J].中国社区医师,2018,34(2):98-99.
[21]卢建敏,孙琳,吴彧,等.参麦注射液联合左卡尼汀治疗老年缺血性心肌病心力衰竭疗效观察[J].中国全科医学,2008,11(14):1287-1288.
[22]董军.左卡尼汀联合参麦注射液治疗缺血性心肌病心力衰竭的临床效果[J].中国医药指南,2013,11(16):210-211.
[2]余世成,冯俊,孙召金,等.参麦注射液对缺血性心肌病左室射血和心肺运动功能的影响[J].安徽医药,2017,21(4):731-734.
[3]张国强,李征,朱志远.左卡尼汀联合参麦注射液治疗缺血性心肌病心力衰竭疗效分析[J].新中医,2014,46(12):33-34.
[4]中华医学会心血管病学分会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):3-10.
[5]乔玉冰,向东.左卡尼汀联合美托洛尔治疗缺血性心肌病心力衰竭的临床疗效观察[J].华南国防医学杂志,2015,6(3):234-236.
[6]吕凤仙.曲美他嗪与左卡尼汀联合用药治疗老年缺血性心肌病心力衰竭患者的疗效分析[J].中国社区医师,2017,33(12):55-56.
[7]胡小洋.参麦注射液与左卡尼汀联用对老年患者缺血性心肌病心力衰竭的临床疗效评价[J].抗感染药学,2016,13(5):1166-1168.
[8]郭文安.缺血性心肌病心力衰竭应用左卡尼汀及参麦注射液治疗的疗效评价[J].中国实用医药,2014,9(7):190.
[9]郭春香.左卡尼汀联合参麦注射液治疗充血性心力衰竭的临床研究[J].中国现代药物应用,2015,9(19):137-138.
[10]赵大鹏.缺血性心肌病心力衰竭应用左卡尼汀与参麦联合治疗的临床分析[J].中国现代药物应用,2016,10(4):154-155.
[11]占凡.参麦注射液联合左卡尼汀治疗老年缺血性心肌病心力衰竭的临床疗效[J].中国老年学,2013,33(16):3990-3991.
[12]田韵,何河.左卡尼汀联合参麦注射液治疗老年缺血性心肌病心力衰竭疗效观察[J].现代中西医结合杂志,2014,23(34):3820-3822.
[13]董赛晓,邓志鹏,白丽秀,等.左卡尼汀注射液联合参麦注射液治疗缺血性心肌病心力衰竭疗效观察[J].中国中医急症,2012,21(5):817-818.
[14]李芳学.左卡尼汀联合参麦注射液治疗缺血性心肌病心力衰竭35例效果观察[J].山东医药,2010,50(51):59-60.
[15]陈俊媛.左卡尼汀联合参麦注射液治疗缺血性心肌病心力衰竭的临床研究[J].中国卫生标准管理,2015,6(13):171-172.
[16]邹宁.参麦注射液联合左卡尼汀治疗慢性心力衰竭临床研究[J].亚太传统医药,2017,13(22):156-157.
[17]吴保军.参麦注射液联合左卡尼汀对缺血性心肌病心力衰竭病人神经内分泌因子、左室重构及心功能的影响[J].中西医结合心脑血管病杂志,2017,15(15):1864-1866.
[18]陆建洪,张树鑫,陈捷.参麦注射液联合左卡尼汀治疗缺血性心肌病心力衰竭疗效观察[J].中华中医药学刊,2016,34(2):470-472.
[19]周婵娟.左卡尼汀联合曲美他嗪治疗老年缺血性心肌病心力衰竭临床分析[J].心血管病防治知识(学术版),2016,7(11):74-75.
[20]周先立.参麦注射液联合左卡尼汀治疗缺血性心肌病心力衰竭的疗效[J].中国社区医师,2018,34(2):98-99.
[21]卢建敏,孙琳,吴彧,等.参麦注射液联合左卡尼汀治疗老年缺血性心肌病心力衰竭疗效观察[J].中国全科医学,2008,11(14):1287-1288.
[22]董军.左卡尼汀联合参麦注射液治疗缺血性心肌病心力衰竭的临床效果[J].中国医药指南,2013,11(16):210-211.